Clinical trial Recruiting at 1 site Interventional Ages 18 and up

Changing magnesium and acid type in dialysis fluid to reduce clotting and immune activation

Official title: Effect of Modifying Magnesium Concentration in Citrate-enriched Dialysate on Hemodialysis-associated Thromboinflammation: a Local Pilot OMAGOD Plus Trial

Run by Universitair Ziekenhuis Brussel · NCT07206524 · Data updated 2026-11-12

This project tests whether changing the magnesium level and acid type in dialysis fluid can reduce immune-driven clotting and inflammation in people on maintenance hemodialysis.

More Hemodialysis trials

Quick facts

Study typeInterventional
Ages18 Years and up
SexAll
Enrollment15 (estimated)
SponsorUniversitair Ziekenhuis Brussel
Academic / other
Locations1 site (Brussels)
StatusRecruiting
StartedJune 5, 2025
Main results expectedNovember 30, 2025
Study endsDecember 2026
Registry record updatedNovember 17, 2025
Trial IDNCT07206524 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates are adults enrolled in the OMAGOD pilot who receive maintenance hemodialysis and can attend the Universitair Ziekenhuis Brussel for the extra sampling sessions.

Probably not a fit

Patients who are not enrolled in the OMAGOD pilot, those on non-hemodialysis modalities, or those unable to attend the additional sampling visits are not eligible and unlikely to benefit from this nested study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This nested monocentric sub-study enrolls participants from the multicenter OMAGOD pilot and uses a crossover design with three dialysate compositions given in two-week periods. Each participant receives standard hemodialysis while switching between citrate-acid and acetic-acid dialysates with different magnesium concentrations. During selected midweek sessions, serial blood samples are taken at baseline, hourly, and at the end of dialysis, and the used dialysis circuit is rinsed to collect adherent cells. Outcomes focus on immune cell activation, neutrophil extracellular trap formation, and other thromboinflammatory markers.

Why it matters

Potential benefit: If successful, this approach could reduce dialysis-associated clotting and inflammation and improve treatment comfort and safety.

How similar studies have gone: Previous studies have reported reductions in clotting and inflammation with citrate-based dialysate and altered magnesium, but applying these specific magnesium concentrations with NET-focused measurements is relatively novel.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Participants to the OMAGOD pilot trial

Exclusion Criteria:

* Patients who are not participating in the OMAGOD pilot trial

Where it's running

  • Universitair Ziekenhuis Brussel
    Brussels, Belgium
    Recruiting

Study contacts

  • Principal investigator: Florine Janssens, Medical doctor — (1)Department of Nephrology and Arterial Hypertension, Universitair Ziekenhuis Brussel (UZ Brussel), Brussels, Belgium. (2) Kidney diseases, dialysis & transplantation Research Unit (NIER), Vitality Research Group, Vrije Universiteit Brussel (VUB)
  • Study coordinator: Florine Janssens, Medical doctor
  • Email: florine.janssens@uzbrussel.be
  • Phone: +324749435

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.